Oxford vaccine shows 90% efficacy in Phase-3 trial
Two doses of the vaccine given in two different regimen showed different efficacies. In the case of the regimen (involving 2,741 participants) where a halved dose was used as a…
Category: Oxford University vaccine ChAdOx1 nCoV-19
Oxford vaccine found safe and immunogenic even in older adults
The results were published online in The Lancet on November 19. The results are based on the study of 560 participants enrolled between May 30 and August 8. Of the…
Pfizer’s COVID-19 vaccine shows promise, many unknowns remain
The results of the Phase-1 trial, announced in August, first through a press release and then through a preprint a week later, showed that the vaccine induced neutralising antibodies and…
It makes sense to bring people to the vaccine instead of taking COVID-19 vaccine to people in some settings: Gagandeep Kang
Government has prioritised certain groups to receive the vaccine first. Which vulnerable groups do you think should receive the vaccine on priority? Frontline healthcare workers at every level should receive vaccines when…
India’s potential participation in COVAX advance market commitment is under way: Trevor Mundel
Trevor Mundel, President of the Global Health Division, Bill & Melinda Gates Foundation, has led the foundation’s efforts to support the development of diagnostics, therapeutics, and vaccines for the global…
Serum Institute has begun manufacturing Oxford coronavirus vaccine
The Pune-based Serum Institute of India has already begun manufacturing the Oxford vaccine (ChAdOx1 nCoV-19) for novel coronavirus. The company intends to manufacture two-three million doses by end-August. The Pune-based…
Results of coronavirus vaccine trials call for cautious optimism
Never before have candidate vaccines been developed from scratch, tested on animals and completed early stages of human clinical trials all under six months. This is an acid test for…
Oxford coronavirus vaccine is safe, immunogenic, preliminary phase-1/2 trial shows
The preliminary results of the Phase-1/2 clinical trial of the Oxford vaccine shows the vaccine is safe, well-tolerated, and immunogenic. The vaccine induced strong antibody by day 28 and remained…
